Crina Claudia Rusu1, Simona Racasan2, Ina Maria Kacso3, Liviu Ghervan4, Diana Moldovan3, Alina Potra3, Ioan Mihai Patiu2, Cosmina Bondor5, Mirela Gherman Caprioara3. 1. Department of Nephrology, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj, 3-5 Clinicilor Street, 400006, Cluj-Napoca, Romania. crinaclaudiarusu@yahoo.ro. 2. Nefromed Dialysis Center, 40 Ana Aslan Street, Cluj-Napoca, Romania. 3. Department of Nephrology, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj, 3-5 Clinicilor Street, 400006, Cluj-Napoca, Romania. 4. Institute of Clinical Urology and Renal Transplantation, 4-6 Clinicilor Street, 400006, Cluj-Napoca, Romania. 5. Department of Informatics and Biostatistics, University of Medicine and Pharmacy "Iuliu Hatieganu" Cluj, 6 Pasteur Street, 400349, Cluj-Napoca, Romania.
Abstract
PURPOSE: Cardiovascular disease (CVD) is the most common cause of death in hemodialysis (HD) patients. Transmembrane proteins that circulate as soluble form such as tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) and CD163 have been proposed in previous studies as CVD biomarkers in chronic kidney disease patients. In HD patients, since studies are scarce, the role of these proteins is not completely understood. We tested the hypothesis that sTWEAK, sCD163 or sCD163/sTWEAK ratio could be associated with cardiovascular disease in HD patients. METHODS: We recorded current clinical and biological data, and we measured sTWEAK and sCD163 serum levels by ELISA in 70 hemodialysis patients. Univariate analysis and multivariate (logistic regression) analysis were used to identify the relation between sTWEAK, sCD163 and sCD163/sTWEAK ratio and CVD. RESULTS: In univariate analysis, CVD in HD patients is associated with higher sCD163/sTWEAK ratio (p = 0.04), sCD163 (p = 0.07), CRP (p = 0.04), age (p = 0.07), smoking (p = 0.09) and vascular calcifications (p = 0.10). In multivariate analysis, only logarithm of sCD163/sTWEAK ratio (p = 0.04) and smoking (p = 0.03) was significantly associated with CVD. The levels of these molecules and their ratio were correlated with atherosclerosis risk factors: diabetes mellitus, high fasting glucose, tricipital skinfold thickness and CRP as well as (for sCD163/sTWEAK) intravenous iron therapy. CONCLUSIONS: Cardiovascular disease is associated with increased sCD163/sTWEAK ratio. To our knowledge, this is the first report about this relationship in HD patients.
PURPOSE:Cardiovascular disease (CVD) is the most common cause of death in hemodialysis (HD) patients. Transmembrane proteins that circulate as soluble form such as tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) and CD163 have been proposed in previous studies as CVD biomarkers in chronic kidney diseasepatients. In HDpatients, since studies are scarce, the role of these proteins is not completely understood. We tested the hypothesis that sTWEAK, sCD163 or sCD163/sTWEAK ratio could be associated with cardiovascular disease in HDpatients. METHODS: We recorded current clinical and biological data, and we measured sTWEAK and sCD163 serum levels by ELISA in 70 hemodialysis patients. Univariate analysis and multivariate (logistic regression) analysis were used to identify the relation between sTWEAK, sCD163 and sCD163/sTWEAK ratio and CVD. RESULTS: In univariate analysis, CVD in HDpatients is associated with higher sCD163/sTWEAK ratio (p = 0.04), sCD163 (p = 0.07), CRP (p = 0.04), age (p = 0.07), smoking (p = 0.09) and vascular calcifications (p = 0.10). In multivariate analysis, only logarithm of sCD163/sTWEAK ratio (p = 0.04) and smoking (p = 0.03) was significantly associated with CVD. The levels of these molecules and their ratio were correlated with atherosclerosis risk factors: diabetes mellitus, high fasting glucose, tricipital skinfold thickness and CRP as well as (for sCD163/sTWEAK) intravenous iron therapy. CONCLUSIONS:Cardiovascular disease is associated with increased sCD163/sTWEAK ratio. To our knowledge, this is the first report about this relationship in HDpatients.
Entities:
Keywords:
Atherosclerosis; Cardiovascular disease; Hemodialysis; sCD163/sTWEAK ratio
Authors: Grazina Urbonaviciene; Jose L Martin-Ventura; Jes S Lindholt; Sigitas Urbonavicius; Juan A Moreno; Jesús Egido; Luis M Blanco-Colio Journal: Atherosclerosis Date: 2011-09-16 Impact factor: 5.162
Authors: Jonas Axelsson; Holger Jon Møller; Anna Witasp; Abdul Rashid Qureshi; Juan Jesus Carrero; Olof Heimbürger; Peter Bárány; Anders Alvestrand; Bengt Lindholm; Søren K Moestrup; Peter Stenvinkel Journal: Am J Kidney Dis Date: 2006-12 Impact factor: 8.860
Authors: Alper Azak; Mehmet Fatih Akdoğan; Nazım Denizli; Bülent Huddam; Gülay Koçak; Murat Gücün; Mustafa Adem Tatlısu; Recep Demirci; Bilal Yılmaz; Mehmet Dikeç; Murat Bakırtaş; Ibrahim Akdağ; Murat Duranay Journal: Int Urol Nephrol Date: 2013-09-17 Impact factor: 2.370
Authors: Nasser M Al-Daghri; Omar S Al-Attas; Lotfi S Bindahman; Majed S Alokail; Khalid M Alkharfy; Hossam M Draz; Sobhy Yakout; Philip G McTernan; Shaun Sabico; George P Chrousos Journal: Eur J Clin Invest Date: 2012-09-04 Impact factor: 4.686
Authors: Peter Lanzer; Manfred Boehm; Victor Sorribas; Marc Thiriet; Jan Janzen; Thomas Zeller; Cynthia St Hilaire; Catherine Shanahan Journal: Eur Heart J Date: 2014-04-16 Impact factor: 29.983